Takeda announces Paradigm shift
Takeda Pharmaceutical Company is to acquire Paradigm Therapeutics, after Paradigm\'s shareholders agreed on 12 March to the move.
Takeda Pharmaceutical Company is to acquire Paradigm Therapeutics, after Paradigm's shareholders agreed on 12 March to the move.
Financial terms were not disclosed. Subject to completion, which is expected to occur within a few weeks, Paradigm will become a subsidiary of Takeda Europe Holdings, a wholly owned subsidiary of Takeda. Paradigm will be renamed Takeda Cambridge, and Paradigm's subsidiary in Singapore will be renamed Takeda Singapore.
Founded in 1999 by University of Cambridge researchers, Paradigm has established target identification and validation capabilities based on genetic engineering and in vivo pharmacology. The British firm has also developed a pipeline of novel drug discovery targets and compounds in key areas of unmet medical need including pain, CNS disorders, prostate and breast cancer, diabetes, hyperlipidemia, and obesity.
Following the merger, which builds upon the two companies' 2005 therapeutic area alliance, Paradigm's technologies and researchers will be integrated into Takeda and will help to speed up a number of projects.
